Company Summary

Actuate Therapeutics is developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β). Activity and overexpression of GSK-3β have been implicated in many conditions, including cancer, Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, and inflammatory conditions leading to fibrosis. GSK-3β is a novel and important target for the development of a new class of drugs that will have a significant impact on the treatment of cancer and select inflammatory diseases. In cancer, GSK-3β is heavily implicated in chemo- and radioresistance in tumor cells. Notably, aberrant nuclear accumulation of GSK-3β is a specific marker of malignant cells, but not of benign cells, making development of targeted therapies for GSK-3β an important and viable approach for cancer treatment.

Year Founded:  2015

Key Executives:
• Daniel M. Schmitt, President and CEO

Location:  Chicago, IL and Ft. Worth, TX

Website:  http://www.actuatetherapeutics.com

Company Status:  Private

Year Invested:  2019

Investment Status:  Current

Board Member:  Alex Adrianopoulos